The data presented between September 30 and October 3 underscore the firm's focus on expanding treatment options for conditions including alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, and psoriasis.
In section Releases
AbbVie Unveils New Dermatological Data at 2026 EADV Congress
AbbVie is presenting 60 research abstracts at the 2026 European Academy of Dermatology and Venereology Congress in Vienna, highlighting advancements in immune-mediated skin diseases. The company’s portfolio update features late-breaking clinical trial results for both established therapies and emerging investigational compounds across six major therapeutic areas.
Key updates include long-term efficacy data for the approved therapies SKYRIZI (risankizumab) and RINVOQ (upadacitinib), alongside initial findings for investigational agents lutikizumab and zumilokibart. According to Ryan DeMasi, vice president of global medical affairs, these findings aim to improve patient outcomes by advancing the scientific understanding of complex inflammatory pathways. The presentation includes three late-breaking studies that examine novel mechanisms of action, reinforcing the company’s ongoing investment in dermatology research.
Comments (0)
No comments yet. Be the first!